Adjuvant Chemotherapy with Modified FOLFIRINOX Regimen Improves Survival
A French clinical trial showed that adjuvant chemotherapy (given after surgery) with modified FOLFIRINOX improves survival of pancreatic cancer patients.
Embracing Optimism
Laurie MacCaskill is a long-term survivor of pancreatic cancer. She followed a personalized treatment plan, and focused her energy on remaining optimistic.
Chemotherapy to Survive; Fitness to Thrive
Mike Levine switched oncologists to find chemotherapy that works on his pancreatic cancer. After that he was able to compete in the Ironman Triathlon.
Chemoradiation Before Tumor Removal to Lessen Possible Post-Surgical Disease
A clinical trial examines the effectiveness of presurgical chemotherapy and radiation in making cancer-free margins after tumor removal.
Treating Tumors Before Pancreatic Cancer Surgery
Can neoadjuvant treatment such as chemoradiation make pancreatic cancer removal surgery more effective? That is the question asked by this clinical trial.
The Relatively New Procedure of Irreversible Electroporation Has Given Me Time
Leslie Wineberg started her pancreatic cancer treatment with chemotherapy and radiation but was glad to qualify for irreversible electroporation (IRE).
A New Clinical Trial Leads to No Evidence of Disease
After her diagnosis of pancreatic cancer, Shannon Magee became patient 1 in a new clinical trial that combined chemotherapy and a Whipple procedure.
Alternating Protocols to Attack Pancreatic Cancer
Working with his oncologist, Dr. Mark Fishman decided to follow non-standard alternating protocols to treat his pancreatic cancer.
I Have Pancreatic Cancer; It Does Not Have Me
Bill Shrieves was ready to start a clinical trial for pancreatic cancer when it was found to have spread. He was successfully treated with FOLFIRINOX.
Comparing a Standard Chemotherapy With and Without a PARP Inhibitor
A clinical trial compares standard chemotherapy with and without the addition of a PARP inihibitor, for patients whose pancreatic cancer is spreading again.
- 1
- 2
